Literature-Guided 6-Gene Signature for the Stratification of High-Risk Acute Myeloid Leukemia
Cancer Research and Treatment · 2025
DOI: 10.4143/crt.2024.1114 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Jong Keon Song und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Biomarkers, Tumor, Transcriptome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Korea Health Industry Development Institute, Ministry of Health and Welfare, National Research Foundation of Korea.
Abstract (Originalsprache)
Purpose
Acute myeloid leukemia (AML) shows significant heterogeneity in therapeutic responses. We aimed to develop a gene signature for the stratification of high-risk pediatric AML using publicly available AML datasets, with a focus on literature-based prognostic gene sets.Materials and Methods We identified 300 genes from 12 well-validated studies on AML-related gene signatures. Clinical and gene expression data were obtained from three datasets: TCGA-LAML, TARGET-AML, and BeatAML. Least absolute shrinkage and selection operator–Cox regression analysis was used to perform the initial gene selection and to construct a prognostic model using the The Cancer Genome Atlas (TCGA) database (n=132). The final gene signature was validated with two independent cohorts: BeatAML (n=411) and TARGET-AML (n=187).
Results
We identified a six-gene signature (ETFB, ARL6IP5, PTP4A3, CSK, HS3ST3B1, PLA2G4A), referred to as the literature-based signature 6 (LBS6), that was significantly associated with lower overall survival rates across the TCGA (high-risk [HR], 4.2; 95% confidence interval [CI], 2.59 to 6.81; p < 0.001), BeatAML (HR, 1.52; 95% CI, 1.17 to 1.96; p=0.001), and TARGET (HR, 2.05; 95% CI, 1.36 to 3.08; p < 0.001) datasets. The high-LBS6 score group exhibited significantly poorer five-year event-free survival compared to the low-LBS6 score group (HR, 2.09; 95% CI, 1.38 to 3.15; p < 0.001). After adjusting for key risk factors, including gene mutations (WT1, FLT3, and NPM1), protocol-based risk group, white blood cell count, and age, the LBS6 score was independently associated with worse survival rates in validation cohorts.
Conclusion
Our literature-driven approach identified a robust gene signature that stratifies AML patients into distinct risk groups. The LBS6 score shows promise in redefining initial risk stratification and identifying high-risk AML patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Förderung
- Korea Health Industry Development Institute
- Ministry of Health and Welfare
- National Research Foundation of Korea
- Ministry of Science and ICT
Zitieren
APA
Song, J. K., Lee, D. H., Kim, H., & Hwang, S. H. (2025). Literature-Guided 6-Gene Signature for the Stratification of High-Risk Acute Myeloid Leukemia. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.1114
Vancouver
Song JK, Lee DH, Kim H, Hwang SH. Literature-Guided 6-Gene Signature for the Stratification of High-Risk Acute Myeloid Leukemia. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.1114
BibTeX
@article{Song2025,
author = {Song, Jong Keon and Lee, Dong Hyeok and Kim, Hyery and Hwang, Sang-Hyun},
title = {Literature-Guided 6-Gene Signature for the Stratification of High-Risk Acute Myeloid Leukemia},
journal = {Cancer Research and Treatment},
year = {2025},
doi = {10.4143/crt.2024.1114}
}
EUVIMED